Vaccine Contract Market Growth to Accelerate in Forecast Period (2025-2035) | Lonza Group AG ,Catalent, Inc.,WuXi Biologics ,Samsung Biologics,Emergent BioSolutions

Industry Outlook
The Vaccine Contract Manufacturing Market accounted for USD 2.94 Billion in 2024 and is expected to reach USD 6.72 Billion by 2035, growing at a CAGR of around 7.8% between 2025 and 2035. Vaccine contract manufacturing is the practice of outsourcing vaccine production to third-party companies, known as contract development and manufacturing organizations (CDMOs). These firms offer services such as vaccine design, formulation, manufacture, and quality assurance.

CDMOs let pharmaceutical and biotechnology companies focus on R&D while producing high-quality, efficient, and cost-effective vaccines on a large scale. The market is being driven by growing demand for vaccinations, which are required in light of many global disease outbreaks, including the current COVID-19 epidemic. Two vaccines, mRNA and viral vector, have boosted the sector's global expansion. Contract manufacturers are often regarded as critical to vaccine production and compliance with stringent criteria. As more poor nations implement immunization programs, the vaccine contract manufacturing business expands.

Get Free Sample PDF Copy of This @ https://www.metatechinsights.com/request-sample/1665

Major Key players :
• Lonza Group AG
• Catalent, Inc.
• WuXi Biologics
• Samsung Biologics
• Emergent BioSolutions
• Ajinomoto Bio-Pharma Services
• Curia Global
• Charles River Laboratories International Inc.
• Fujifilm Diosynth Biotechnologies
• Recipharm AB
• Gedeon Richter
• Serum Institute of India
• Bharat Biotech
• Hester Biosciences

Segment Analysis
By Product type, the Vaccine Contract Manufacturing Market is segmented into Conventional vaccine and Novel vaccine. Live-attenuated, inactivated, and toxoid vaccines have long been used to prevent viral infections such as measles, poliomyelitis, and tetanus. These vaccinations remain popular, particularly in developing countries where they serve as the primary vaccines. On the other side, the development of innovative vaccinations (recombinant vaccines, DNA vaccines, and mRNA vaccines) is currently being driven by advances in biotechnology. Most importantly, as evidenced by the present COVID-19 vaccines, mRNA vaccines are expected to significantly drive market growth in the coming years, and mRNA technology may provide an opportunity to produce new vaccines in terms of capacity and efficiency in the future.

Regional Analysis

The North American vaccine contract manufacturing market is rapidly expanding due to rising vaccination demand in the post-COVID-19 timeframe. The region's top participants, both contract manufacturers and biopharmaceutical companies, are increasing capacity to meet demand. North America's robust constructions, combined with biosimilars that use cutting-edge biomanufacturing technology, make it the preferred region for vaccinations. The United States is the largest market for pandemic vaccines, owing to government policies that encourage funding and collaboration to increase vaccine production capacity. Canada and Mexico also appear as newcomers in this field. They are also investing in automobile manufacturing plants and the biotechnology sector. The legal environment of the region, quality of human capital, and availability of advanced technologies add to its advantage in the global vaccine production chain.

Competitive Landscape

The key players in the global vaccine contract manufacturing market are Lonza Group AG, Catalent, Inc., WuXi Biologics, Samsung Biologics, Emergent BioSolutions, Ajinomoto Bio-Pharma Services, Curia Global, and Charles River Laboratories. These companies are exploiting the increase in the need for vaccinations caused by global responses to existing and emerging epidemics and other illnesses. For instance, Lonzo collaborates with Moderna to increase the production of the mRNA vaccines, and Catalent diversified its production channels to support COVID-19 vaccine production and shipment.

Get a Customization Report
@ https://www.metatechinsights.com/customize-report/1665

Report Coverage:
By Product Type
• Conventional Vaccines
o Live-Attenuated Vaccines
o Inactivated Vaccines
o Toxoid Vaccines
• Novel Vaccines
o Recombinant Vaccines
o DNA Vaccines
o mRNA Vaccines
By Service Type
• Process Development
• Manufacturing Services
• Analytical and Quality Control Services
• Others
By Scale of Operation
• Preclinical
• Clinical
• Commercial
By Indication
• Infectious Diseases
o Influenza
o COVID-19
o Hepatitis
o Tuberculosis
o Dengue
o Malaria
o Others
• Non-Infectious Diseases
o Cancer Vaccines
o Allergies
o Autoimmune Diseases
By End User
• Pharmaceutical Companies
• Biotechnology Companies
• Research Institutes
• Public Health Organizations

By Region
North America (US, Canada, Mexico)
Europe (U.K, France, Germany, Italy, Rest of Europe.)
Asia-Pacific (China, Japan, India, Australia, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Mexico, Rest of Latin America)
Middle East & Africa (GCC Countries, South Africa, Rest of Middle East & Africa)

Inquiry Before Buying
@ https://www.metatechinsights.com/inquiry-before-buying/1665

Address :
50 MacAleese Lane #24, Moncton, New Brunswick, E1A 3L9, Canada

Contact Us:
Web: www.metatechinsights.com
Ph: US - +1 5064 048 481
Email: sales@metatechinsights.com

About Us:
Metatech Insights specializes in making comprehensive global and regional market research reports in Healthcare, Medical Devices, Healthcare IT, Agriculture, Chemicals and Materials, Consumer Goods, Food & Beverages, Pet Care, Cryptocurrency, and Novel technologies. Our meticulously designed research reports are regarded as one of the most detailed and well-thought market research studies available in the industry. Our reports typically include market assessments, analysis of industry trends, and competitive intelligence.

This release was published on openPR.